A DMF, or Drug Master File, is a confidential document submitted to the FDA that contains detailed information about the ingredients, manufacturing processes, or packaging materials used to make a drug. It is not a drug application and does not get approved or disapproved on its own. Instead, it exists so that companies can share sensitive technical information with the FDA without revealing trade secrets to their business partners. DMF can also stand for dimethyl fumarate, a medication used to treat multiple sclerosis, which is covered at the end of this article.
How a Drug Master File Works
Pharmaceutical manufacturing involves many companies. One company might produce an active ingredient, another might supply the capsule material, and a third might actually market the finished drug. Each of these players holds proprietary information they don’t want competitors (or even their own business partners) to see. A Drug Master File solves this problem by letting a supplier submit confidential details directly to the FDA, where they stay protected.
When a drug company files an application for a new or generic drug, it needs to prove that every component meets safety and quality standards. Rather than obtaining a supplier’s secret manufacturing data and including it in the application, the drug company simply references the supplier’s DMF. The FDA then reviews both the drug application and the referenced DMF together, connecting the dots without either company having to share proprietary information with the other.
The Letter of Authorization
A DMF holder controls who can reference their file through a formal Letter of Authorization. This letter tells the FDA that a specific company has permission to incorporate information from the DMF into its own drug application. Without this letter, the FDA will not review the DMF in connection with that application. The authorization can be granted to multiple companies, which is how a single ingredient supplier can support dozens of generic drug applications simultaneously.
The Five Types of DMFs
The FDA organizes Drug Master Files into categories based on what kind of information they contain.
- Type I was previously used for manufacturing site information but is no longer accepted for new submissions.
- Type II covers drug substances (active pharmaceutical ingredients), intermediates used in their preparation, and finished drug products. This is by far the most common type, especially in the generic drug industry.
- Type III covers packaging materials. If a packaging component manufacturer wants to keep its formulation or process confidential, it can file this type rather than handing that data to the drug company.
- Type IV covers inactive ingredients like excipients, colorants, flavors, and essences, along with materials used in their preparation.
- Type V is a catch-all for other FDA-accepted reference information, such as sterility assurance data.
DMFs Are Not Drug Approvals
One of the most common points of confusion is that a DMF is not a substitute for a drug application. Filing a DMF does not mean the FDA has reviewed or endorsed its contents. The agency only evaluates the technical information inside a DMF when it is referenced by an actual drug application, such as a New Drug Application (NDA) for a brand-name drug or an Abbreviated New Drug Application (ANDA) for a generic. Think of a DMF as a locked filing cabinet at the FDA. It sits there until someone submits an application that points to it, at which point the FDA opens it and checks what’s inside.
Filing Fees and Costs
Type II DMFs that support generic drug applications carry a filing fee under the Generic Drug User Fee Amendments program. For fiscal year 2025, that fee is $95,084. This cost falls on the DMF holder, typically the active ingredient manufacturer. Other DMF types do not carry the same fee structure.
Why DMFs Get Flagged as Incomplete
The FDA performs a completeness assessment on Type II DMFs before they can support a generic drug application. If the DMF fails this assessment, it delays not just the file itself but every drug application that references it. Common reasons for failure include missing data on how the ingredient behaves in different crystal forms (polymorphic characterization), incomplete information about impurities and residual solvents, and gaps in the manufacturing description such as missing details about reagents, catalysts, or reaction conditions. The FDA also flags submissions that lack a nitrosamine risk assessment or fail to list all contractors involved in manufacturing and testing, including their facility registration numbers.
These deficiencies matter to anyone in the generic drug supply chain because a single incomplete DMF can hold up an entire product launch.
DMF as Dimethyl Fumarate
In a medical context, DMF often refers to dimethyl fumarate, a prescription medication used to treat relapsing forms of multiple sclerosis. It works by reducing inflammation and protecting nerves from the damage that causes MS symptoms like numbness, muscle weakness, and coordination problems. The drug comes as a delayed-release capsule designed to release in the intestine rather than the stomach. It is prescribed for several MS patterns, including clinically isolated syndrome (a single episode of neurological symptoms lasting at least 24 hours), relapsing-remitting MS, and secondary progressive MS with active relapses.